Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients : Rationale and Design of the HEP-COVID Trial
Thieme. All rights reserved..
Coronavirus disease-2019 (COVID-19) has been associated with significant risk of venous thromboembolism (VTE), arterial thromboembolism (ATE), and mortality particularly among hospitalized patients with critical illness and elevated D-dimer (Dd) levels. Conflicting data have yet to elucidate optimal thromboprophylaxis dosing. HEP-COVID (NCT04401293) is a phase 3, multicenter, pragmatic, prospective, randomized, pseudo-blinded, active control trial to evaluate efficacy and safety of therapeutic-dose low-molecular-weight heparin (LMWH) versus prophylactic-/intermediate-dose LMWH or unfractionated heparin (UFH) for prevention of a primary efficacy composite outcome of VTE, ATE, and all-cause mortality 30 ± 2 days post-enrollment. Eligible patients have COVID-19 diagnosis by nasal swab or serologic testing, requirement for supplemental oxygen per investigator judgment, and Dd >4 × upper limit of normal (ULN) or sepsis-induced coagulopathy score ≥4. Subjects are randomized to enoxaparin 1 mg/kg subcutaneous (SQ)/two times a day (BID) (creatinine clearance [CrCl] ≥ 30 mL/min) or 0.5 mg/kg (CrCl 15-30 mL/min) versus local institutional prophylactic regimens including (1) UFH up to 22,500 IU (international unit) daily (divided BID or three times a day), (2) enoxaparin 30 and 40 mg SQ QD (once daily) or BID, or (3) dalteparin 2,500 IU or 5,000 IU QD. The principal safety outcome is major bleeding. Events are adjudicated locally. Based on expected 40% relative risk reduction with treatment-dose compared with prophylactic-dose prophylaxis, 308 subjects will be enrolled (assuming 20% drop-out) to achieve 80% power. Distinguishing design features include an enriched population for the composite endpoint anchored on Dd >4 × ULN, stratification by intensive care unit (ICU) versus non-ICU, and the ability to capture asymptomatic proximal deep venous thrombosis via screening ultrasonography prior to discharge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
|---|---|
| Enthalten in: |
Thrombosis and haemostasis - 121(2021), 12 vom: 31. Dez., Seite 1684-1695 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goldin, Mark [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1475-2351 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323788769 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323788769 | ||
| 003 | DE-627 | ||
| 005 | 20240330000153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-1475-2351 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM323788769 | ||
| 035 | |a (NLM)33823560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goldin, Mark |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients |b Rationale and Design of the HEP-COVID Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a Coronavirus disease-2019 (COVID-19) has been associated with significant risk of venous thromboembolism (VTE), arterial thromboembolism (ATE), and mortality particularly among hospitalized patients with critical illness and elevated D-dimer (Dd) levels. Conflicting data have yet to elucidate optimal thromboprophylaxis dosing. HEP-COVID (NCT04401293) is a phase 3, multicenter, pragmatic, prospective, randomized, pseudo-blinded, active control trial to evaluate efficacy and safety of therapeutic-dose low-molecular-weight heparin (LMWH) versus prophylactic-/intermediate-dose LMWH or unfractionated heparin (UFH) for prevention of a primary efficacy composite outcome of VTE, ATE, and all-cause mortality 30 ± 2 days post-enrollment. Eligible patients have COVID-19 diagnosis by nasal swab or serologic testing, requirement for supplemental oxygen per investigator judgment, and Dd >4 × upper limit of normal (ULN) or sepsis-induced coagulopathy score ≥4. Subjects are randomized to enoxaparin 1 mg/kg subcutaneous (SQ)/two times a day (BID) (creatinine clearance [CrCl] ≥ 30 mL/min) or 0.5 mg/kg (CrCl 15-30 mL/min) versus local institutional prophylactic regimens including (1) UFH up to 22,500 IU (international unit) daily (divided BID or three times a day), (2) enoxaparin 30 and 40 mg SQ QD (once daily) or BID, or (3) dalteparin 2,500 IU or 5,000 IU QD. The principal safety outcome is major bleeding. Events are adjudicated locally. Based on expected 40% relative risk reduction with treatment-dose compared with prophylactic-dose prophylaxis, 308 subjects will be enrolled (assuming 20% drop-out) to achieve 80% power. Distinguishing design features include an enriched population for the composite endpoint anchored on Dd >4 × ULN, stratification by intensive care unit (ICU) versus non-ICU, and the ability to capture asymptomatic proximal deep venous thrombosis via screening ultrasonography prior to discharge | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Enoxaparin |2 NLM | |
| 700 | 1 | |a Giannis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Diab, Wassim |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Janice |e verfasserin |4 aut | |
| 700 | 1 | |a Khanijo, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Sharifova, Gulru |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Lund, Jeet M |e verfasserin |4 aut | |
| 700 | 1 | |a Mignatti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Gianos, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Tafur, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Cohoon, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Kittelson, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Lesser, Martin L |e verfasserin |4 aut | |
| 700 | 1 | |a Sison, Cristina P |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Husneara |e verfasserin |4 aut | |
| 700 | 1 | |a Ochani, Kanta |e verfasserin |4 aut | |
| 700 | 1 | |a Hiatt, William R |e verfasserin |4 aut | |
| 700 | 1 | |a Dale, Rita A |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Victoria E |e verfasserin |4 aut | |
| 700 | 1 | |a Bonaca, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Halperin, Jonathan L |e verfasserin |4 aut | |
| 700 | 1 | |a Weitz, Jeffrey I |e verfasserin |4 aut | |
| 700 | 1 | |a Spyropoulos, Alex C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d 1979 |g 121(2021), 12 vom: 31. Dez., Seite 1684-1695 |w (DE-627)NLM000103896 |x 2567-689X |7 nnns |
| 773 | 1 | 8 | |g volume:121 |g year:2021 |g number:12 |g day:31 |g month:12 |g pages:1684-1695 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1475-2351 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 121 |j 2021 |e 12 |b 31 |c 12 |h 1684-1695 | ||